Cardiff Oncology, Inc.
CRDF
$1.79
-$0.03-1.38%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 60.93% | -27.27% | -25.77% | -46.83% | -3.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 60.93% | -27.27% | -25.77% | -46.83% | -3.21% |
| Cost of Revenue | -9.41% | -14.97% | 21.98% | 30.83% | -428.22% |
| Gross Profit | 9.71% | 14.75% | -22.82% | -32.87% | 436.94% |
| SG&A Expenses | -0.53% | 24.66% | 3.20% | 28.24% | 10.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.57% | -5.26% | 17.23% | 30.10% | 21.31% |
| Operating Income | 37.74% | 4.98% | -17.79% | -31.55% | -21.68% |
| Income Before Tax | 38.78% | 5.04% | -18.38% | -34.19% | -26.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.78% | 5.04% | -18.38% | -34.19% | -26.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.78% | 5.04% | -18.38% | -34.19% | -26.24% |
| EBIT | 37.74% | 4.98% | -17.79% | -31.55% | -21.68% |
| EBITDA | 37.97% | 4.92% | -18.03% | -31.93% | -21.97% |
| EPS Basic | 50.76% | 33.47% | 20.24% | 9.90% | -4.02% |
| Normalized Basic EPS | 50.77% | 33.46% | 20.22% | 9.86% | -4.06% |
| EPS Diluted | 50.76% | 33.47% | 20.24% | 9.90% | -4.02% |
| Normalized Diluted EPS | 50.77% | 33.46% | 20.22% | 9.86% | -4.06% |
| Average Basic Shares Outstanding | 24.37% | 42.71% | 48.41% | 48.90% | 21.35% |
| Average Diluted Shares Outstanding | 24.37% | 42.71% | 48.41% | 48.90% | 21.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |